250 related articles for article (PubMed ID: 22500152)
1. K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome.
Duggan-Keen M
Core Evid; 2006; 1(3):169-80. PubMed ID: 22500152
[TBL] [Abstract][Full Text] [Related]
2. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.
Liu ZM; Hu M; Chan P; Tomlinson B
Expert Opin Investig Drugs; 2015 May; 24(5):611-21. PubMed ID: 25604802
[TBL] [Abstract][Full Text] [Related]
3. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
4. PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.
Nikolic D; Castellino G; Banach M; Toth PP; Ivanova E; Orekhov AN; Montalto G; Rizzo M
Curr Pharm Des; 2017 Mar; 23(6):894-902. PubMed ID: 27719644
[TBL] [Abstract][Full Text] [Related]
5. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
6. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Pershadsingh HA
Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
[TBL] [Abstract][Full Text] [Related]
7. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Towfighi A; Ovbiagele B
Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
[TBL] [Abstract][Full Text] [Related]
8. The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys.
Bodkin NL; Pill J; Meyer K; Hansen BC
Horm Metab Res; 2003 Oct; 35(10):617-24. PubMed ID: 14605998
[TBL] [Abstract][Full Text] [Related]
9. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
10. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
11. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR).
Tenenbaum A; Fisman EZ; Motro M
Cardiovasc Diabetol; 2003 Mar; 2():4. PubMed ID: 12834541
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.
Coll T; Rodrïguez-Calvo R; Barroso E; Serrano L; Eyre E; Palomer X; Vázquez-Carrera M
Curr Mol Pharmacol; 2009 Jan; 2(1):46-55. PubMed ID: 20021445
[TBL] [Abstract][Full Text] [Related]
15. PPAR agonists and the metabolic syndrome.
Staels B
Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
[TBL] [Abstract][Full Text] [Related]
16. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.
Shiomi Y; Yamauchi T; Iwabu M; Okada-Iwabu M; Nakayama R; Orikawa Y; Yoshioka Y; Tanaka K; Ueki K; Kadowaki T
J Biol Chem; 2015 Jun; 290(23):14567-81. PubMed ID: 25907553
[TBL] [Abstract][Full Text] [Related]
17. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
18. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
19. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
Jay MA; Ren J
Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]